Finding Human Monoclonals for Infectious Disease Vaccines
This article was originally published in Start Up
A recent publication shows the ability to make high-affinity, virus-specific human monoclonal antibodies in a matter of weeks from antibody-secreting plasma cells. The research suggests, at least theoretically, that an antibody vaccine could be developed for any infectious disease, using blood from either immunized or infected individuals.
You may also be interested in...
The Vaccines and Related Biological Products Advisory Committee will discuss the use of Madin-Darby canine kidney cells in the manufacturing of live attenuated influenza virus vaccines. When the committee met in 2005 to discuss using the cells, it overwhelmingly agreed that companies should move forward with development, but also recommended that studies be done in animals inoculated with the final vaccine product (1"The Pink Sheet," Nov. 21, 2005, p. 22). It also recommended monitoring patients because of potential oncogenic risks from the tumorigenic canine cell lines
The U.S. influenza vaccine market appears stable in terms of the amount of available product, but the nature of the product this year will be quite different
Vaccines generally are one of the few areas in pharmaceutical development where government incentives, science, and intellectual property are in alignment to favor commercialization. This is particularly true for flu vaccine, where recent events have drawn the attention of government and Big Pharma. That, plus the advent of new adjuvant technology and innovative manufacturing methods, signals opportunity for new players.